title: The effect of LfcinB9 on human ovarian cancer cell SK-OV-3 is mediated by inducing apoptosis.
abstract: LfcinB9 is a peptide derived from lactoferricin B. In the present study, the effect and relative mechanism of LfcinB9 on human ovarian cancer cell line (SK-OV-3) in vitro and in vivo was investigated. The data obtained indicated that LfcinB9 exhibited low hemolysis activity and significantly inhibited the proliferation of SK-OV-3 cells in vitro. In addition, the apoptosis of SK-OV-3 cells was induced through up-regulating the production of reactive oxygen species and activating caspase-3, caspase-9 on both transcription and translation level. Finally, LfcinB9 significantly prevented the tumor growth in the SK-OV-3-bearing mice model. These results indicated that LfcinB9 could be a potential agent for the treatment of ovarian cancer.
authors: China Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
authors: Minjia
authors: M
authors: Sheng
authors: Yanjie
authors: Y
authors: Zhao
authors: Aichen
authors: A
authors: Zhang
authors: Liyan
authors: L
authors: Wang
authors: Guizhen
authors: G
authors: Zhang
mesh_terms: D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D015415:Biomarkers / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D015552:Injections, Intralesional; D007781:Lactoferrin / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D008819:Mice, Nude; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D023181:Antimicrobial Cationic Peptides; D015415:Biomarkers; D009842:Oligopeptides; D010446:Peptide Fragments; C000598076:tryptophyl-glutaminyl-tryptophyl-arginyl-methionyl-lysyl-lysyl-leucyl-glycine; C082171:lactoferricin B; D007781:Lactoferrin
keywords: Caspase-3/9; LfcinB9; ROS; apoptosis; ovarian cancer